Skip to main content
SpringerLink
Log in
Book cover

Therapiekonzepte Onkologie pp 155–164Cite as

Myelodysplastische Syndrome

  • Chapter

  • 69 Accesses

Zusammenfassung

Heterogene Gruppe von Erkrankungen mit den gemeinsamen Charakteristika einer monoklonalen Hämatopoese mit normo- oder hyperzellulärem Knochenmark und peripherer Zytopenie einer oder mehrerer hämatopoetischer Zellreihen aufgrund einer Störung von Proliferation und Differenzierung pluripotenter Stammzellen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aul C, Gattermann N, Schneider W (1992) Age — related incidence and other epidemiological aspects of myelodysplastic syndromes. Brit J Haemat 82:358–367

    Article  PubMed  CAS  Google Scholar 

  2. Crane M, Keating MJ (1991) Exposure history in acute nonlymphocytic leukemia patients with a priori preleukemic condition. Cancer 67:2211–2214

    Article  PubMed  CAS  Google Scholar 

  3. Pedersen-Bjergaard J (1992) Radiotherapy- and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leukemia Res 16:61–65

    Article  CAS  Google Scholar 

  4. Ratain MJ, Rowley JD (1992) Therapy-related acute myeloid leukemia secondary to inhibitors of toposiomerase II: from the bedside to the target genes. Ann Oncol 3:107–111

    Article  PubMed  CAS  Google Scholar 

  5. Mecucci C, van den Berghe H (1992) Cytogenetics. Hematol Oncol Clin North Am 6:523–541

    CAS  Google Scholar 

  6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) French-American-British (FAB) cooperative group. Proposals for the classification of myelodysplastic syndromes. Br J Haemat: 189–199

    Google Scholar 

  7. Goasguen JE, Bennett JM (1992) Classification and morphologic features of the myelodysplastic syndromes. Sem Oncol 19:4–13

    CAS  Google Scholar 

  8. Wörmann B (1993) Myelodysplastisches Syndrom und sekundäre Leukämie. Internist 34:518–525

    PubMed  Google Scholar 

  9. Mufti GJ (1992) A guide to risk assessment in the primary myelodysplastic syndrome. Hematology/Oncology Clinics of North America 6:587–606

    PubMed  CAS  Google Scholar 

  10. List AF, Garewal HS, Sandberg AA (1990) The myelodysplastic syndromes: biology and implications for management. J Clin Oncol 8:1424–1441

    PubMed  CAS  Google Scholar 

  11. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7:1315–1323

    PubMed  CAS  Google Scholar 

  12. Vadhan Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JH (1987) Effects of recombinant human granulocyte — macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1552

    Article  Google Scholar 

  13. Schuster MW (1993) Will cytokines alter the treatment of myelodysplastic syndrome? Am J Med Sciences 305:72–78

    Article  CAS  Google Scholar 

  14. Mertelsmann R, Thaler H, To L et al. (1980) Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56:773–781

    PubMed  CAS  Google Scholar 

  15. Armitage JO, Dick FR, Needleman SW, Burns CP (1981) Effect of chemotherapy for the dysmyelopoietic syndrome, Cancer Treat Rep 65:601–605

    PubMed  CAS  Google Scholar 

  16. Tricot G, Boogaerts MA (1986) The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haemat 63:477–483

    Article  CAS  Google Scholar 

  17. Fenaux P, Lai L, Jouet JP, Pollet JP, Bauters F (1988) Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 57:297–302

    Article  PubMed  CAS  Google Scholar 

  18. Aul C, Schneider W (1989) The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 64: 1812–1818

    Article  PubMed  CAS  Google Scholar 

  19. Büchner T, Hiddemann W, Blasius S et al. (1990) The role of chemotherapy intensity and duration. Two studies of the AMLCG. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute Leukemias II. Springer Verlag, Heidelberg Berlin: 261–266

    Chapter  Google Scholar 

  20. Cheson BD (1992) Chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Sem Oncol 19:85–94

    CAS  Google Scholar 

  21. Appelbaum FR, Barrall J, Storb R et al. (1990) Bone marrow transplantation for patients with myelodysplasia. Ann Int Med 112:590–597

    Article  PubMed  CAS  Google Scholar 

  22. de Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lönnqvist B, Beelen D, Ferrant A, Gmür J, Liu Yin J, Troussard X, Chan J, van Lint M, Gratwohl A for the Working Party on Leukaemia (1990) Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantatioin Group (EBMTG). Br J Haemat 74:151–155

    Article  Google Scholar 

  23. Ratanatharathorn V, Karanes C, Uberti J, Lum LG, de Planque MM, Schultz KR, Cronin S, Dan ME, Mohamed A, Hussein M, Sensenbrenner LL (1993) Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81:2194–2199

    PubMed  CAS  Google Scholar 

  24. List AF, Heaton R, Glinsmann-Gibson B, Brasfield F, Crook L, Taetle R, Kurman M (1997) A phase I/II clinical trial of amifostine in patients with myelodysplastic syndrome (MDS): promotion of multilineage hematopoieses. Proc Am Soc Clin Oncol 16:7a

    Google Scholar 

  25. Raza A, Gezer S, Venugopal P, Kaizer H, Hines C, Thomas R, Alvi S, Mundle S, Shetty V, Borok R, Loew J, Reza S, Robin EL, Rifkin SD, Alston D, Hernandez B, Shah R, Hsu WT, Dar S, Gregory SA (1997) Hematopoietic and cytogenetic responses to novel anti-cytokine therapy in myelodysplastic syndromes (MDS). Proc Am Soc Clin Oncol 16:7a

    Google Scholar 

  26. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring systems for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088

    PubMed  CAS  Google Scholar 

  27. De Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M, Solbu G, Zwierzina H, Muus P (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9:1805–1811

    PubMed  Google Scholar 

  28. Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM, Schiffer CA, Bloomfîeld CD (1996) Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B study. J Clin Oncol 14:2486–2494

    PubMed  CAS  Google Scholar 

  29. Aul C, Runde V, Germing U, Burk M, Heyll A, Hildebrandt B, Willers R (1995) Remission rates, survival and prognostic factors in 90 patients with advanced MDS treated with intensive chemotherapy. Ann Hematol 70 (Suppl 2) : A138

    Google Scholar 

Download references

Authors
  1. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hiddemann, W. (1998). Myelodysplastische Syndrome. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation